Gapping up
In reaction to earnings/guidance:
- HIMX +9.3%, ANGO +4.2%, WBA +3.4%, STZ +3.3%, COLL +1.7%
Other news:
- OXFD +27.1% (to be acquired by PerkinElmer (PKI) for $22.00 per share in cash)
- PLUG +23.1% (to form partnership with SK Group to accelerate hydrogen as energy source in Asian markets; SK Group will make a $1.5 bln investment in PLUG)
- CVAC +15.1% (Bayer AG and CureVac to collaborate on COVID-19 vaccine candidate CVnCoV)
- DTIL +7.6% (announces closing of in vivo gene editing collaboration and license agreement with Eli Lilly and Company (LLY))
- PRSP +7.4% (Veritas Capital discloses 11.7% stake)
- TEN +7% (Carl Ichan discloses 14.99% stake)
- NIU +6.8% (reports Q4 e-scooter sales increased 40.9%)
- ALDX +5.8% (announces positive top-line symptom and sign results from run-in cohort of phase 3 tranquility trial in dry eye disease)
- AFMD +5.1% (provides pipeline and business update; Continued progress for AFM13 and AFM24 clinical studies)
- GLYC +4.9% (announced APL-106 has been granted Breakthrough Therapy Designation from the China NMPA Center for Drug Evaluation for the treatment of relapsed/refractory acute myeloid leukemia)
- AMRN +3.9% (update ahead of JP Morgan conference)
- KZIA +3.6% (announces that the GBM AGILE pivotal study (NCT03970447) has commenced recruitment to the paxalisib arm)
- KALA +3.5% (announced the launch of EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease)
- WBA +3.4% (to accelerate pace and scale of VillageMD rollout)
- AQST +3.4% (provides business update; Multiple clinical trials demonstrate that AQST-108 can consistently deliver epinephrine)
- GBIO +3.1% (prices offering of 8 mln shares of common stock at $24.50 per share)
- ALC +2.7% (launches AcrySof IQ Vivity)
- ALNY +2.1% (reports positive topline results from HELIOS-A phase 3 study of vutrisiran in patients with hATTR amyloidosis with polyneuropathy; met primary and all secondary endpoints at 9 months)
- CHMA +1.9% (provides corporate update and previews expected 2021 milestones)
- CI +1.6% (initiates dividend of $1.00/sh)
- EDUC +1.4% (reports Dec revenue)
- GNL +1.3% (announces that it collected 97% of the original cash rent due for the fourth quarter of 2020 as of January 6, 2021)
- MELI +1.3% (has entered into privately negotiated transactions to repurchase approximately $440 mln principal amount of its outstanding 2.00% convertible senior notes due 2028)
- USB +1.2% (to acquire Debt Servicing client portfolio of MUFG Union Bank)
- TMUS +1% (provides Q4 operating metrics), .
Analyst comments:
- MOS +3.6% (upgraded to Overweight from Neutral at JP Morgan)
- TSLA +3% (upgraded to Sector Perform from Underperform at RBC Capital Mkts)
- JPM +2.2% (upgraded to Buy from Neutral at BofA Securities)
- FL +2.1% (upgraded to Outperform from Market Perform at Cowen)
- WFC +1.9% (upgraded to Buy from Hold at Jefferies)
- ANET +1.4% (upgraded to Buy from Neutral at Rosenblatt)
- CS +1.3% (upgraded to Overweight from Neutral at JP Morgan)
- MCD +1.2% ( upgraded to Outperform from Perform at Oppenheimer)